Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 18/20 | 0.54 |
| ▸ | NR3C2 | P08235 | 17/20 | 0.54 |
| ▸ | PGR | P06401 | 14/20 | 0.54 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3957430 | 0.87 | NR3C1 (0.51) | NR3C1NR3C2PGRPARP1AR | |
| SCHEMBL4668326 | 0.86 | NR3C1 (0.44) | NR3C1NR3C2PGRPARP1AR | |
| SCHEMBL14081376 | 0.84 | NR3C1 (0.59) | NR3C1NR3C2PGRPARP1AR | |
| SCHEMBL563723 | 0.82 | NR3C1 (0.62) | NR3C1NR3C2PGRPARP1PTGS1 | |
| SCHEMBL3690152 | 0.82 | NR3C1 (0.57) | NR3C1NR3C2PGRPARP1AR | |
| SCHEMBL14081359 | 0.82 | NR3C1 (0.62) | NR3C1NR3C2PGRPARP1PTGS1 | |
| SCHEMBL3953152 | 0.81 | NR3C1 (0.54) | NR3C1NR3C2PGRPARP1AR | |
| SCHEMBL14115126 | 0.81 | NR3C1 (0.61) | NR3C1NR3C2PGRPARP1PTGS1 | |
| SCHEMBL14208907 | 0.80 | NR3C1 (0.54) | NR3C1NR3C2PGRPARP1AR | |
| SCHEMBL13767636 | 0.80 | NR3C1 (0.36) | NR3C1NR3C2PGRPARP1AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140200354-A1 | Process for the Manufacture of Non-Steroidal Anti-Inflammatory Agents and Intermediates Thereof | INTENDIS GMBH (DE) | 2014-07-17 | — | — | US | disclosed |
| US-20120035371-A1 | PROCESS FOR THE MANUFACTURE OF NON-STEROIDAL ANTI-INFLAMMATORY AGENTS AND INTERMEDIATES THEREOF | SCHWEIZER STEFFEN (DE) | 2012-02-09 | — | — | US | disclosed |
| US-8071796-B2 | Process for the manufacture of non-steroidal anti-inflammatory agents and intermediates thereof | INTENDIS GMBH (DE) | 2011-12-06 | — | — | US | disclosed |
| EP-2142503-A2 | PROCESS FOR THE MANUFACTURE FOR NON-STEROIDAL ANTI-INFLAMMATORY AGENTS AND INTERMEDIATES THEREOF | Intendis GmbH (DE) | 2010-01-13 | — | — | EP | disclosed |
| EP-1844039-B1 | 5-SUBSTITUTED QUINOLINE AND ISOQUINOLINE DERIVATIVES, A METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS ANTIPHLOGISTICS | BAYER SCHERING PHARMA AG (DE) | 2009-07-15 | — | — | EP | disclosed |
| US-20080274517-A1 | PROCESS FOR THE MANUFACTURE OF NON-STEROIDAL ANTI-INFLAMMATORY AGENTS AND INTERMEDIATES THEREOF | INTENDIS GMBH (DE) | 2008-11-06 | — | — | US | disclosed |
| WO-2008128750-A2 | PROCESS FOR THE MANUFACTURE FOR NON-STEROIDAL ANTI-INFLAMMATORY AGENTS AND INTERMEDIATES THEREOF | INTENDIS GMBH (DE) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080274517-A1 | PROCESS FOR THE MANUFACTURE OF NON-STEROIDAL ANTI-INFLAMMATORY AGENTS AND INTERMEDIATES THEREOF | CYP2F1, CYP4A11, CYP11B1 | NR3C1 74/4885NR3C2 23/4885PGR 2139/4885 |
| US-20120035371-A1 | PROCESS FOR THE MANUFACTURE OF NON-STEROIDAL ANTI-INFLAMMATORY AGENTS AND INTERMEDIATES THEREOF | CYP2F1, CYP4A11, CYP11B1 | NR3C1 74/4885NR3C2 23/4885PGR 2139/4885 |
| US-20140200354-A1 | Process for the Manufacture of Non-Steroidal Anti-Inflammatory Agents and Intermediates Thereof | CYP2F1, CYP4A11, CYP11B1 | NR3C1 71/4885NR3C2 20/4885PGR 2022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.